Wolfgang Guba

This inventor holds 50 USPTO granted patents and 35 published patent applications, plus 1 CIPO patent and 17 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoffmann-La Roche Inc., Siena Biotech S.p.a., ETH Zurich. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wolfgang Guba. Retrieved from https://idiyas.com/inventor/wolfgang-guba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 50 (Patent Applications = 35)

% Patents Active = 42.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 17 (Patent Applications = 21)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 78(Granted Patents)

Location History:

Mueliheim, DE (2017)
Muelheim, DE (2013 - 2018)
Mullheim, DE (2007 - 2019)
Mülheim, DE (2019)
Müllheim, DE (2019)
Basel, CH (2019 - 2023)
Muellheim, DE (2005 - 2024)

Company Filing History:

50 out of 5,024

Hoffmann-La Roche Inc.

Vernalis Research Limited

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

BACE1 Inhibitors

Ethynyl Derivatives

CNS Disorders

Triazolopyrimidone

Cannabinoid Agonists

Thiadiazines

Oxazines

Positive Allosteric Modulators

Pyridine Derivatives

Pyridyl-Triazabicycles

Arylethynyl Derivatives

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12741952 - Compounds (2026-09-22),

2. 12655126 - Imidazole-pyrazole derivatives as antibacterials (2026-06-16),

3. 12509467 - CGAS inhibiting triazolopyrimidone derivatives (2025-12-30),

4. 12421209 - Compounds (2025-09-23),

5. 12006323 - Ethynyl derivatives (2024-06-11),

6. 11655243 - Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists (2023-05-23),

7. 11034699 - Ethynyl derivatives (2021-06-15),

8. 11034687 - BACE1 inhibitors (2021-06-15),

9. 10829500 - Pyridyl-triazabicycles (2020-11-10),

10. 10723729 - BACE1 inhibitors (2020-07-28),

11. 10696691 - BACE1 inhibitors (2020-06-30),

12. 10457686 - [1,2,3]triazolo[4,5-D]pyrimidine derivatives (2019-10-29),

13. 10457685 - [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor (2019-10-29),

14. 10457684 - [1,2,3]triazolo[4,5-d]pyrimidine derivatives (2019-10-29),

15. 10450321 - [1,2,3]triazolo[4,5-D]pyrimidine derivatives (2019-10-22),

Title: The Inventive Journey of Wolfgang Guba

Introduction:

Wolfgang Guba, a prolific inventor hailing from Muellheim, Germany, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 46 patents. His innovative spirit and dedication to advancing medical treatments have positioned him as a prominent figure in the industry.

Latest Patents:

Guba's latest patents showcase his expertise in developing cutting-edge solutions for a variety of health conditions. One of his notable inventions includes ethynyl derivatives, which are positive allosteric modulators of metabotropic glutamate receptor 4 (mGluR4). These compounds hold promise for treating a range of disorders such as Parkinson's disease, anxiety, and depression. Additionally, his work on pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists demonstrates his commitment to exploring novel therapeutic options for various medical ailments.

Career Highlights:

Throughout his career, Wolfgang Guba has garnered experience working with industry giants such as Hoffmann-La Roche Inc. His tenure at Hoffmann-La Roche Inc. has been instrumental in shaping his innovative mindset and strengthening his expertise in pharmaceutical research and development. Guba's relentless pursuit of groundbreaking solutions has solidified his reputation as a trailblazer in the field.

Collaborations:

In his pursuit of excellence, Wolfgang Guba has collaborated with esteemed professionals in the industry, including Thomas Johannes Woltering and Eric Vieira. These fruitful partnerships have enabled Guba to exchange ideas, leverage collective expertise, and push the boundaries of pharmaceutical innovation. Through collaboration, Guba has been able to amplify the impact of his inventions and drive meaningful change in healthcare.

Conclusion:

Wolfgang Guba's journey as an inventor is characterized by a relentless pursuit of innovation and a steadfast commitment to improving the lives of individuals through groundbreaking pharmaceutical solutions. His latest patents underscore his versatility and ingenuity in addressing a wide range of health conditions, solidifying his standing as a visionary in the field. Guba's collaborative spirit and storied career serve as a testament to his enduring impact on the world of inventions and patents.

Profile summary based on public USPTO records.